GoodRx (NASDAQ:GDRX) Reaches New 12-Month Low After Analyst Downgrade

GoodRx Holdings, Inc. (NASDAQ:GDRX)’s stock price hit a new 52-week low during trading on Wednesday after Citigroup lowered their price target on the stock from $10.00 to $7.00. Citigroup currently has a buy rating on the stock. GoodRx traded as low as $4.61 and last traded at $4.63, with a volume of 871841 shares trading hands. The stock had previously closed at $4.70.

Several other brokerages have also weighed in on GDRX. Barclays lowered their target price on shares of GoodRx from $10.00 to $6.00 and set an “overweight” rating on the stock in a research report on Monday. Royal Bank of Canada reiterated an “outperform” rating and issued a $10.00 price target on shares of GoodRx in a research report on Friday, August 16th. Raymond James upgraded shares of GoodRx from an “outperform” rating to a “strong-buy” rating and set a $10.00 price target on the stock in a research report on Friday, August 9th. Finally, UBS Group lowered their price target on shares of GoodRx from $9.00 to $8.50 and set a “neutral” rating on the stock in a research report on Friday, August 9th. One investment analyst has rated the stock with a sell rating, four have given a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $8.86.

Insider Activity

In other news, major shareholder Equity Vii L.P. Spectrum sold 10,677 shares of the firm’s stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $7.86, for a total value of $83,921.22. The sale was disclosed in a filing with the SEC, which is accessible through this link. Insiders own 4.17% of the company’s stock.

Institutional Investors Weigh In On GoodRx

A number of large investors have recently added to or reduced their stakes in GDRX. Mirae Asset Global Investments Co. Ltd. grew its holdings in GoodRx by 61.1% during the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 181,512 shares of the company’s stock valued at $1,289,000 after purchasing an additional 68,835 shares in the last quarter. Quantbot Technologies LP grew its holdings in GoodRx by 175.2% during the 1st quarter. Quantbot Technologies LP now owns 84,148 shares of the company’s stock worth $597,000 after acquiring an additional 53,574 shares in the last quarter. Swiss National Bank grew its holdings in GoodRx by 3.9% during the 1st quarter. Swiss National Bank now owns 155,000 shares of the company’s stock worth $1,100,000 after acquiring an additional 5,800 shares in the last quarter. Susquehanna Fundamental Investments LLC acquired a new position in GoodRx during the 1st quarter worth $466,000. Finally, US Bancorp DE grew its holdings in GoodRx by 3.7% during the 1st quarter. US Bancorp DE now owns 109,818 shares of the company’s stock worth $780,000 after acquiring an additional 3,877 shares in the last quarter. 63.77% of the stock is owned by institutional investors and hedge funds.

GoodRx Stock Performance

The company has a market capitalization of $1.77 billion, a price-to-earnings ratio of -153.67, a price-to-earnings-growth ratio of 3.24 and a beta of 1.39. The company has a debt-to-equity ratio of 0.70, a quick ratio of 5.48 and a current ratio of 5.48. The company’s fifty day simple moving average is $6.76 and its two-hundred day simple moving average is $7.48.

GoodRx Company Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.